axv-128
mAbexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT02978885)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Annexin A5INHIBITOR
ANXA5 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 99-MTC
Oral
No
Parenteral
No
Topical
No
Also known as
- axv-128
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02978144 | Phase 2 | Jan 1, 2017 | Columbia University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT02978885 | Phase 2 | Jan 1, 2017 | Columbia University, National Heart, Lung, and Blood Institute (NHLBI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Columbia University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1